Anavex Life Sciences (NASDAQ:AVXL) Earns “Buy” Rating from HC Wainwright

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $42.00 price target on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 412.82% from the company’s current price.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday.

Anavex Life Sciences Trading Down 1.3 %

NASDAQ AVXL opened at $8.19 on Monday. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44. The company has a market cap of $696.67 million, a PE ratio of -14.89 and a beta of 0.80. The stock’s 50-day moving average price is $8.84 and its two-hundred day moving average price is $8.43.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. Research analysts forecast that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AVXL. Vermillion Wealth Management Inc. acquired a new position in Anavex Life Sciences during the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC boosted its holdings in shares of Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company’s stock worth $36,000 after buying an additional 1,708 shares during the period. Orion Capital Management LLC grew its stake in Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 10,000 shares during the last quarter. PVG Asset Management Corp bought a new position in Anavex Life Sciences in the 3rd quarter worth $74,000. Finally, BNP Paribas Financial Markets lifted its position in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 7,421 shares during the last quarter. 31.55% of the stock is owned by institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.